AA Positionsa | PAML Site Model (M8) p> 0.9 | PAML Branch-Site Modelc | FELd p< 0.2 | RELd BF > 50 | AA Changes | Parallel Changes | Property Changese | Protein Domain | Functional Informationf | Cladeg |
---|---|---|---|---|---|---|---|---|---|---|
25 | Â | Â | Â | Â | Ser-Arg | Yes | SM, P, NEU-P.POS | LRR3 | Â | B, C |
28 | Â | Â | 0.07 | Â | Leu-Trp | Â | NP, NEU-P, NEU | LRR3 | Â | A, D |
 |  |  |  |  | Leu-Pro |  | NP, NEU-SM, NP, NEU |  |  |  |
45 | Â | Â | 0.16 | Â | Thr-Ile | Yes | SM, P, NEU-NP, NEU | LRR4 | Â | A, F |
104 | Â | Â | 0.17 | Â | Leu-Val | Â | NP, NEU-NP, NEU | LRR6 | Â | Â |
 |  |  |  |  | Leu-Ser |  | NP, NEU-SM, P, NEU |  |  |  |
128 | Â | 0.875 | Â | Â | Glu-Pro | Â | P, NEG-SM, NP, NEU | LRR7 | Â | D |
133 | Â | 0.723 | Â | Â | Asn-Lys | Â | SM, P, NEU-P, POS | LRR7 | Â | G |
139 | Â | 0.708 | Â | Â | Gly-Glu | Â | SM, NP, NEU-P, NEG | LRR8 | Adjacent to site involved in interaction with MD2 | G |
149 | Â | 0.565 | Â | Â | Ser/Leu -Thr | Â | SM, P, NEU/NP, NEU -SM, P, NEU | LRR8 | Â | G |
150 | 0.995 | Â | Â | 228.23 | His-Arg | Yes | P, POS-P, POS | LRR8 | Â | A, B, C |
 |  |  |  |  | His-Asp |  | P, POS-SM, P, NEG |  |  |  |
177 | Â | Â | Â | 61.94 | Asn-Thr Asn/Thr -Ile Asn-Lys Ile-Asn | Â | SM, P, NEU-SM, P, NEU SM, P, NEU/SM, P, NEU -NP, NEU SM, P, NEU-P, POS NP, NEU-SM, P, NEU | LRR9 | Adjacent to site involved in ligand binding and interaction with MD2 | A, C, G |
179 | 0.992 | Â | 0.07 | 647.96 | Lys-Glu Glu-Gln Glu/Lys- Gln | Yes | P, POS-P, NEG P, NEG-P, NEU P, NEG/P, POS-P, NEU | LRR9 | Â | A, C, F |
183 | Â | Â | 0.12 | 51.06 | Arg-Ser Arg-Thr | Â | P, POS-SM, P, NEU P, POS-SM, P, NEU | LRR9 | Â | C, D |
204 | Â | Â | Â | Â | Glu-His | Yes | P, NEG-P, POS | LRR10 | Â | A, D |
207 | 1.000 | Â | 0.08 | 1563.58 | Gly/Lys -Arg Arg-Lys Arg-Thr Lys-Arg | Â | SM, NP, NEU/P, POS -P, POS P, POS-P, POSP, POS-SM, P, NEU P, POS-P, POS | LRR10 | Â | A, G, C, E |
212 | Â | Â | Â | Â | Leu-Val | Yes | P, POS-NP, NEU | LRR10 | Â | A, B |
221 | Â | Â | 0.1 | Â | Val-Met | Yes | NP, NEU-NP, NEU | LRR11 | Â | C, D, F |
228 | 0.994 | Â | 0.15 | 544.88 | Asp/Ser/Cys -Asn Asp-Asn | Â | SM, P, NEG/SM, P, NEU/SM, NP, NEU -SM, P, NEU SM, P, NEG-SM, P, NEU | LRR11 | Â | A, G |
230 | 0.978 | Â | Â | Â | Gly/Glu/Asp -Arg Asp-His | Â | SM, NP, NEU/P, NEG/SM, P, NEG -P.POS SM, P, NEG-P, POS | LRR11 | Â | A, E |
239 | Â | Â | Â | 50.32 | Cys-Tyr | Yes | SM, NP, NEU-P, NEU | LRR12 | Â | B, D, G |
247 | Â | Â | 0.14 | 86.14 | Ile-Thr Thr-Ile | Â | NP, NEU-SM, P, NEU SM, P, NEU-NP, NEU | LRR12 | Adjacent to site involved in interaction with ligand binding | C, G |
250 b | 0.936 | Â | Â | Â | Asp/Ala -Lys Asp/Lys/Ala -Asn Asn-Lys | Â | SM, P, NEG/SM, NP, NEU -P, POS SM, P, NEG/P, POS/SM, NP, NEU -SM, P, NEU SM, P, NEU-P, POS | LRR12 | Ligand binding | A, E, G |
265 | Â | Â | Â | Â | Phe-Leu | Yes | NP, NEU-NP, NEU | LRR13 | Â | B, E |
272 | 0.997 | Â | 0.13 | 188.28 | Gly/Asp- His Gly-His His-Gly | Â | SM, NP, NEU/SM, P, NEG-P, POS SM, NP, NEU-P, POS P, POS-SM, NP, NEU | LRR13 | Adjacent to site involved in interaction with ligand binding | A, C |
280 | 0.952 | Â | 0.18 | 191.07 | Glu-Ala Gln/Glu- Ala | Yes | P, NEG-SM, NP, NEU P, NEU/P, NEG-SM, NP, NEU | LRR13 | Â | A, B, E |
302 | Â | 0.624 | Â | Â | His-Arg | Â | P, POS-P.POS | LRR14 | Â | D |
304 | Â | Â | Â | 55.05 | Asp-Asn Asn-Pro | Â | SM, P, NEG-SM, P, NEU SM, P, NEU-SM, NP, NEU | LRR14 | Â | G |
324 | 0.996 | Â | Â | 301.87 | Asn-Ser Asn-Lys Gly-Asn | Â | SM, P, NEU-SM, P, NEU SM, P, NEU-P, POS SM, NP, NEU-SM, P, NEU | LRR15 | Adjacent to site involved in interaction with ligand binding (hydrogen bond) | C, E, G |
342 | Â | Â | Â | 53.56 | Asn-Ser Asn/Ser- Thr | Â | SM, P, NEU-SM, P, NEU SM, P, NEU/SM, P, NEU-SM, P, NEU | LRR16 | Adjacent to site involved in interaction with ligand binding (hydrogen bond) | A |
351 | Â | Â | Â | 0.17 | Ile/Ala-Val | Â | NP, NEU/SM, NP, NEU-NP, NEU | LRR16 | Adjacent to site involved in interaction with ligand binding (hydrophobic interaction) | G |
368 | Â | 0.576 | Â | Â | Ile-Thr | Â | NP, NEU-SM, P, NEU | LRR17 | Adjacent to site involved in interaction with ligand binding (hydrophobic interaction) | G |
404 | Â | Â | Â | 0.08 | Leu-Met | Â | NP, NEU-NP, NEU | LRR18 | Â | C |
408 | Â | Â | Â | Â | Ile-Thr | Yes | NP, NEU-SM, P, NEU | LRR19 | Â | A, G |
409 | Â | Â | Â | 0.19 | Leu/Ile/Phe -Val | Â | NP, NEU/NP, NEU/NP, NEU -NP, NEU | LRR19 | Â | A |
482 | Â | Â | Â | 0.16 | Ser/Trp- Phe Phe/Ser/Trp -Leu | Â | SM, P, NEU/P, NEU-NP, NEU NP, NEU/SM, P, NEU/P, NEU -NP, NEU | LRR22 | Â | A |
542 | 0.903 | Â | Â | Â | Met-Thr | Yes | NP, NEU-SM, P, NEU | LRRCT | Â | A, D |
551 | 0.938 | Â | Â | Â | Ile-Val Val-Ile | Yes | NP, NEU-NP, NEU NP, NEU-NP, NEU | Transmembrane | Â | B, F |
559 | Â | Â | Â | 0.16 | Val-Ala | Â | NP, NEU-SM, NP, NEU | Transmembrane | Â | G |
690 | Â | 0.564 | Â | Â | Arg-Gln | Â | P, POS-P, NEU | TIR | Â | D |
740 | Â | 0.790 | Â | Â | Glu-Asp | Â | P, NEG-SM, P, NEG | TIR | Â | G |
742 | Â | 0.697 | Â | Â | Asn-Arg | Â | SM, P, NEU-P, POS | TIR | Â | G |
743 | Â | Â | Â | 0.18 | Gln-Glu | Â | P, NEU-P, NEG | TIR | Â | A, F |